CurrentCignaPolicy IP0416

Citalopram 30 mg oral capsule coverage

Defines medical necessity, authorization, and reauthorization rules for citalopram 30 mg oral capsules for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyCitalopram 30 mg oral capsule coverage

Policy CodePolicy IP0416

Change TypeNo material change

Effective DateApr 1, 2024

Next Review DateApr 1, 2025

Key ActionObtain prior authorization and document either direction to 10 mg or 20 mg tablets or a prescriber-justified clinical inability to use those tablets.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30 mgspecific formulation addressed

12 monthsinitial authorization duration

12 monthsreauthorization duration

Employer Group Plansnon-covered product context

Coverage Criteria for Citalopram 30 mg Oral Capsule

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Employer Group Plans initial criteria: Direct the individual to citalopram 10 mg or 20 mg tablets

Preferred tablet formulations should be used instead of 30 mg capsule

Employer Group Plans initial criteria: Approve if the prescriber documents a significant clinical concern such that the individual is unable to use citalopram 10 mg and/or 20 mg tablets

Prescriber documentation of the clinical concern is required

Initial Therapy — Initial authorization conditions for citalopram 30 mg oral capsules

Initial authorization conditions

Initial approval: Direction to use citalopram 10 mg or 20 mg tablets OR prescriber documents a significant clinical concern preventing use of those tablets

Initial approval up to 12 months

Reauthorization Criteria

Continuation (reauthorization) criteria

Reauthorization: Above medical necessity criteria are met AND documentation of beneficial response is provided

Reauthorization approval up to 12 months

Use of the citalopram 30 mg capsule is non‑covered for Employer Group Plans when neither of the policy’s specified conditions is present. Specifically, coverage is not approved if there is no direction to use citalopram 10 mg or 20 mg tablets and the prescriber has not documented a significant clinical concern (i.e., an inability to use the 10 mg and/or 20 mg tablets).

Provider Requirements and Authorization Actions

Prior Authorization

Prior Authorization Required

Prior authorization is required to approve citalopram 30 mg oral capsules. Initial and reauthorization approvals are up to 12 months.

Initial authorization duration: up to 12 months
Reauthorization duration: up to 12 months

Step Therapy

Step Preference for Tablet Formulations

Coverage requires directing the member to citalopram 10 mg or 20 mg tablets OR the prescriber must document a significant clinical concern that prevents use of those tablet formulations.

Step preference: citalopram 10 mg or 20 mg tablets
If tablets cannot be used, prescriber documentation of inability to use 10 mg and/or 20 mg tablets is required

Documentation Required

Prescriber Justification Required for 30 mg Capsule

If approval is requested under a significant clinical concern (inability to use 10 mg and/or 20 mg tablets), prescriber documentation supporting the concern is required.

Prescriber must document the clinical reason why 10 mg and/or 20 mg tablets cannot be used

Documentation Required

Reauthorization Documentation

Documentation of beneficial response is required for reauthorization of citalopram 30 mg oral capsules.

Reauthorization requires evidence of clinical benefit while on the 30 mg capsule

Denial Risk

Non-Coverage for Employer Group Plans

If neither of the specified criteria is met (direction to use 10 mg or 20 mg tablets, or prescriber documents a significant clinical concern), the 30 mg capsule is non-covered for Employer Group Plans.

Non-coverage applies when step preference or prescriber-justified exception is not met

Denial Risk

Experimental/Unproven Use

Any use not meeting the medical necessity criteria in this policy is considered experimental, investigational or unproven and may be denied.

Uses outside the stated criteria are experimental/investigational/unproven

Initial Therapy Criteria

Initial Therapy — Initial authorization conditions

Initial authorization conditions

Initial approval: Direction to use citalopram 10 mg or 20 mg tablets OR prescriber documents significant clinical concern preventing use of those tablets

Initial approval up to 12 months

Reauthorization / Continuation Criteria

Reauthorization / Continuation — Continuation therapy rules for citalopram 30 mg oral capsules

Continuation therapy rules for citalopram 30 mg oral capsules

Continuation: Medical necessity criteria are met AND documentation of beneficial response is provided

Reauthorization approval up to 12 months

Step Therapy and Formulation Preference

Step	Requirement
1	Direct the individual to citalopram 10 mg or 20 mg tablets prior to approving citalopram 30 mg oral capsule
1 (exception)	Approve citalopram 30 mg oral capsule if the prescriber documents a significant clinical concern such that the individual is unable to use citalopram 10 mg and/or 20 mg tablets

Background

Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants used to treat a range of mood and anxiety disorders. Citalopram (an SSRI) is available in multiple oral formulations and strengths; this policy addresses the 30 mg oral capsule formulation and its coverage relative to lower‑strength tablet options. The policy prefers directing individuals to 10 mg or 20 mg tablets when appropriate, reserving the 30 mg capsule for cases with documented significant clinical concerns preventing use of the tablet strengths.

Definitions

SSRI — Pharmacologic class

ClassSelective serotonin reuptake inhibitors (SSRIs)

Primary actionAntidepressant action via selective inhibition of serotonin reuptake

Common usesTreatment of a wide range of mood and anxiety disorders (see FDA-approved indications)

Representative agent in this policyCitalopram (Celexa) — includes tablets, oral solution, and capsules

Relevance to policyDefines the pharmacologic class underpinning coverage decisions for citalopram 30 mg oral capsules